Abecma Approved for Earlier Lines in R/R Multiple Myeloma Abecma Approved for Earlier Lines in R/R Multiple Myeloma

The drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news